2,3-dehydrosilybin is a better DNA topoisomerase I inhibitor than its parental silybin

Chemotherapy. 2009;55(1):42-8. doi: 10.1159/000175466. Epub 2008 Nov 21.

Abstract

Background: We have shown that compared with silybin, 2,3-dehydrosilybin (DHS) exhibits more potent in vitro anticancer activities alone or in combination with tumor necrosis factor (TNF)-alpha. Since TNF-alpha sensitization is related to DNA topoisomerase (topo) inhibition, DHS may be a potent topo inhibitor.

Methods: Under significant apoptosis induction by DHS, we measured specific topo I activity in nuclear extracts or purified enzyme.

Results: Treatment of more transformed FIB cells with 30 microM DHS for 24 h caused significant decreases in topo I activity in nuclear extracts while silybin did not have any effects. Less transformed EPI cells were more resistant against DHS-induced topo I inhibition. Inhibitory effects of topo I activity by DHS were also found in cell-free assays using purified topo I, whereas silybin again did not have any effects.

Conclusion: DHS is a potent topo I inhibitor rendering its ability to sensitize TNF-alpha for enhanced cytotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cells, Cultured
  • DNA Topoisomerases, Type I / metabolism*
  • Data Interpretation, Statistical
  • Humans
  • Silybin
  • Silymarin / chemistry
  • Silymarin / pharmacology
  • Time Factors
  • Topoisomerase I Inhibitors
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Antineoplastic Agents
  • Silymarin
  • Topoisomerase I Inhibitors
  • Tumor Necrosis Factor-alpha
  • dehydrosilybin
  • Silybin
  • DNA Topoisomerases, Type I